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Abstract 
Introduction: Preterm infants (PIs) are at increased risk of vaccine preventable diseases (VPDs). However 
delayed vaccination start and low vaccine coverage are still reported. 
Areas covered: This systematic review includes 37 articles on preterm vaccination published in 2008-2018 
in PubMed. Both live attenuated and inactivated vaccines are safe and well tolerated in PIs. Local reactions, 
apnea and reactivity changes are the most frequently reported adverse events. Lower gestational age and 
birth weight, preimmunization apnea, longer use of continuous positive airway pressure (CPAP) are risk 
factor for apnea. The proportion of PIs who develop protective humoral and cellular immunity is generally 
similar to full terms although later gestational age is associated to increased antibody IgG concentrations 
(i.e. against certain pneumococcal serotypes, influenza, hepatitis B virus and poliovirus 1) and increased 
mononuclear cells proliferation (i.e. after inactivated poliovirus). However vaccinated PIs have lower 
hospitalizations, ambulatory visits and notifications of VPDs. 
Expert opinion: PIs can be safely and adequately protected by available vaccines with the same schedule 
used for full terms. However data at this regard have been almost exclusively retrieved by studies using a 3-
dose primary series for pneumococcal and hexavalent vaccines, while further studies are needed regarding 
the 2+1 schedule. Apnea represents a nonspecific stress response in PIs, thus those hospitalized at 2 
months should have cardio-respiratory monitoring for 2 days after their first vaccination. 
 
Keywords: preterm infant, vaccinations, safety, immunogenicity, efficacy, effectiveness. 
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Information Classification: General 
Article highlights 
x Despite recommendation to vaccinate preterm infants at the same scheduled age as full-term 
children, a delay is commonly experienced in these population. 
x Preterm children may experience vaccine preventable diseases, which tend to be more severe, due 
to an impaired immune response 
x Based on our research the overall safety and tolerability of the scheduled vaccines showed no 
differences in preterm and full-term infants, and live attenuated vaccines as well are considered 
safe. 
x Postponing vaccination is justified only in clinically unstable infants 
x Preterm infants already hospitalized at the time of first vaccination should receive their first dose in 
the neonatal ward, particularly those infants born≤31 weeks of gestation, those with a birth weight 
2 ≤kg, those suffering from apnoea/bradycardia and those with severe bronchopulmonary 
dysplasia. There should then be monitoring of the clinical conditions and the cardio-respiratory 
system as inpatients for two days. 
 
 
 
1- Introduction 
Among the nearly 13 million preterm births occurring each year worldwide, approximately 500,000 occur in 
Europe where the preterm birth rate varies between 5% and 9% [1,2]. In Italy, the 
proportion of preterm (<37 weeks gestation) and very preterm (<32 weeks gestation) births are about 7% 
and 1%, respectively, corresponding approximately to 38,000 and 5500 live births annually [3].  Preterm 
infants (PIs) may develop several long term adverse consequences, such as cerebral palsy, sensory deficits, 
respiratory illnesses, cognitive and behavioral disabilities [4–6], and are at increased risk of infections due 
to defects in external barriers, lower levels of passively transferred maternal antibody, innate and adaptive 
immunity impairment, with the latter resulting in suboptimal B and T cell function [7-9]. Therefore, preterm 
infants may experience vaccine preventable diseases (VPD) with increased frequency and severity in the 
first months of life [10–12], such as pertussis [13], pneumococcal infections [14], and influenza [15]. 
According to the international recommendations preterm infants, who are otherwise healthy, should follow 
the same vaccination schedule used for full-term infants, based on their chronological age rather than 
corrected gestational age and regardless of their birth weight. Moreover, vaccine dosages normally given to 
full term infants should not be reduced or divided when given to PIs [16-21]. 
However, low vaccination coverage and schedules’ delayed start have been reported in PIs [22-29].  
Delayed beginning of vaccines’ schedules seems to be associated with low birthweight, lower gestational 
age, hospitalization after discharge from the neonatal intensive care units (NICUs), paternal/maternal 
unemployment, increasing numbers of siblings in the family, lower socioeconomic status and ethnicities 
other than white [22, 30]. Fear of a weaker response to vaccines or of adverse events in preterm infants 
could be other reasons for the delay [31–34]; however several studies show that PIs are generally able to 
mount a protective adaptive immune response to most vaccines used in infant vaccination programmes 
[31, 35-36]. Moreover even if some adverse events like apnea and/or bradycardia have been reported to 
occur between 0 and 47% following vaccination in PIs, they are self-limiting non specific stress responses 
that commonly complicate other medical procedures without any long term sequelae [33-39]. The aim of 
the present study is to systematically review the available literature about vaccinations in PIs focusing on 
safety and immunogenicity/effectiveness. 
 
2- Methods 
A literature search was performed covering papers published from January 1st 2008 to 31st  October 2018. 
The PubMed MEDLINE and Cochrane Library databases were systematically searched using the following 
terms combined using Boolean operators ("infant, preterm"[MeSH Terms]) AND "vaccination"[MeSH 
terms]). Only papers published in English were included. Reference lists of the retrieved articles were 
reviewed to identify other possible pertinent publications. Titles and abstracts of studies identified during 
the primary search were screened for inclusion, and papers containing prospective or retrospective 
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observational studies and clinical trials focusing on vaccination in PIs were included in this review.  We 
included also studies assessing a comparison between full-term and PIs. Articles not pertinent to vaccines in 
PIs, commentaries, letters, case series (including less than 10 infants), case reports, reviews, duplicates and 
papers not written in English were excluded. Data were independently extracted by two different authors 
(CP and ES) and any disagreements or conflicts were discussed with a third author (EC). The following data 
were extracted for each study: year of publication, study type and location, gestational age (GA) of the 
study population, number of children included, type of vaccination administered, study outcomes (i.e.: 
laboratory indicators of immunogenicity; clinical indicators of efficacy or effectiveness; reported adverse 
events for vaccines’ safety), follow up and possible biases and limitations of the study. The PRISMA 
Statement has been used for reporting of the systematic review filling a 27-item checklist (Table 1) and a 
four-phase flow diagram (Figure 1) [40]. 
 
3-Results 
Initially, 61 studies were identified through the search strategy (Table 2) and additionally another 15 
studies were retrieved after evaluation of the studies’ references; 39 articles were excluded relying on 
studies’ abstracts or titles because they didn’t satisfy eligibility criteria (Figure 1). 
Finally, 37 relevant articles were included in this systematic review: 24 articles had as the main objective 
vaccines’ safety in preterm infants [34-35, 41-62]; while 18 and 4 articles investigated immunogenicity [31, 
41-42, 46-50, 53-54, 63-67, 70,72,73] and effectiveness [45, 68-69, 71] as the main objective respectively. 
3.1-Studies on vaccine safety. 
Safety was the main objective of 24 studies, overall including 789,165 preterm infants (Table 3) [34, 35, 41-
62]. 
3.1.1-Studies on live attenuated vaccines’safety. 
Live attenuated vaccines were investigated in 6 studies [41-46]. Measles vaccination’s safety was evaluated 
by Ichikawa et al. in a prospective study including 17 PIs <34 weeks of gestation who received an early 
vaccination at 6 months of age in order to prevent the disease. No adverse reaction was reported, but the 
number of vaccinated infants in the present study was limited [41]. 
Saroha et al. in a prospective randomized trial found that Bacille Calmette-Guérin (BCG) vaccine may be 
safely given at birth to moderately PIs (31–33 weeks). The only complication observed in 3.4% of the 117 
patients enrolled in the study was left axillary lymphadenopathy [42]. Another two studies aimed to 
determine the safety of BCG vaccination [43-44]. Kjærgaard et al. performed two randomized multicenter 
clinical trials in Denmark, overall involving 4262 children, of which 144 were aged 32 to 37 weeks of 
gestation. No difference was observed on either susceptibility of infections, growth, body composition or 
psychomotor development between patients that received or did not receive BCG vaccination at birth [43-
44]. 
Two studies investigated safety of rotavirus vaccination in PIs [45-46].  A large population-based study by 
Rouè et al. showed no significant difference in severe adverse events incidence following rotavirus 
vaccination between preterm and full-term infants. [45].  Omenaca et al. in their phase IIIb randomized 
double blinded placebo-controlled trial including 165 PIs vaccinated with live-attenuated rotavirus 
observed a similar frequency of severe adverse events (SAEs) in the vaccinated and placebo groups (P = 
0.266) [46]. The proportion of all and grade 3 solicited general adverse events (AEs) reported during the 15-
day postvaccination follow-up period were similar in both the vaccinated and placebo groups, with 
irritability as the most common AE [46]. The most commonly reported unsolicited AEs were fever, 
irritability, gastrointestinal disorders and upper respiratory tract infections. 
3.1.2-Studies on inactivated or subunit vaccines’ safety. 
Inactivated or subunit vaccines were investigated in 18 studies [34-35,47-62] (Table 3). Tsuda et al. in a 
prospective cohort study reported local redness as the only AE after Haemophilus influenzae (Hib) 
vaccination in 54 PIs [47]. Influenza A/H1N1 MF59-adjuvanted vaccination were studied by Esposito et al. in 
an open randomized trial including 101 infants.  No difference in safety and tolerability were found 
between term and PIs. The only systemic adverse event consistently observed in all groups was fever, 
which was significantly more frequent after the first dose than after the second in all the groups [48]. 
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An open-label prospective multicenter randomized controlled trial by Kent et al. evaluated the safety of  
the conjugate vaccine containing thirteen pneumococcal serotypes (PCV13) on PIs aged <35 weeks of 
gestation with different timing of administration: reduced schedule of PCV13 ( at 2 and 4 months of age),  
accelerated schedule (at 2, 3 and 4 months of age) and extended schedule (at 2, 4 and 6 months of age) 
[49]. There was no significant difference in the frequency or severity of local and systemic AEs between 
vaccination schedules at any time point and no serious AEs were considered vaccine related [49]. 
Several studies found a similar or sometimes lower frequency of AEs related to multivalent vaccines in PIs 
compared to full term infants, probably as the result of a reduced immune response and ability to mount 
an inflammatory process [50-54]. 
Klein et al. described adverse events related to diphtheria, tetanus, acellular pertussis (DTaP), hepatitis B 
(HBV), inactivated polio (IPV), pneumococcal vaccine (PCV) during the 30 days after each of 3 doses, 
comparing the frequency of AEs in preterm and full-term infants in 83 patients: no increase of medical 
attended events (MAEs) was found in the two groups comparing to the control period (postvaccination 
days 31–60)[50]. Moreover, in one retrospective study by McCrossan et al. none of the 344 PIs displayed an 
AE [51]. In a large observational self-controlled case series by Wilson et al. children acted as their own 
control counting the rate of events per day in an “at risk” period (i.e. immediate 3 days post vaccination at 
2 months of age with DTaP-HBV-IPV-PCV) compared with the rate of events in a control period during 
which it would be unlikely that the exposure produced the outcome (9–18 days post-vaccination)[52]. 
Overall 771,453 children, of which 49,220 children <37 weeks of GA and 7,392 children ≤ 32 weeks of GA, 
were enrolled in the study, showing a progressive reduction in admission to emergency room department 
or to hospital 3 days after vaccination at 2 months of age with increasing category of prematurity [52]. 
Omeñaca et al. enrolled 313 term and PIs in an open controlled prospective multicenter study. Local 
symptoms in the 4 days following the combined Haemophilus influenzae type B-Neisseria meningitidis 
serogroup C vaccine (Hib-MenC-TT) were lower compared with DTaP-HBV-IPV-PCV vaccine [53]. Large 
injection-site swellings after the booster dose were reported less frequently in the preterm group than in 
full-term group, occurring mainly at the DTaP-IPV injection site. No difference in grade 3 AEs were found 
between groups [53]. Similarly, in another study, assessing the safety of the 10-valent pneumococcal non 
typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 149 term and 137 PIs, the 
incidence of solicited general symptoms (i.e: fever, irritability, drowsiness, loss of appetite) was generally 
similar across the groups [54]. Considering local symptoms, such as redness or swelling, their incidence was 
lower in PIs than in the term group [54]. None of the reported serious AEs was considered causally related 
to vaccination. The most frequently reported unsolicited AEs in all groups were upper respiratory tract 
infections, together with injection site nodules after primary and booster vaccination in the term group. 
One episode of apnea was reported in a PI after the first primary dose, but it was not considered to be 
associated to the vaccination and resolved without sequelae [54]. 
Wilinska et al. studied 138 children born before 37 weeks of gestation (73 born ≤28 weeks GA and 65 born 
>28 weeks GA), who underwent vaccination as inpatient and monitored their cardiac and respiratory 
functions as well as body temperature over 72 hours after DTaP-IPV-PCV-Hib vaccination. Apnea and 
changes in reactivity (i.e. change in infants’ behavior valued by Multidimensional Neonatal Infant Pain 
Scale-NIPS) were the relatively most frequent reported AEs. Infants who experienced apneas had 
significantly more frequently late onset sepsis and a history of longer use of continuous positive airway 
pressure (CPAP)[55]. 
Several studies found an increased incidence of apnea in PIs following vaccination with DTaP-IPV-PCV-Hib 
vaccine [34-35, 56-60]. Incidence of these reactions even if different in the reported studies declined with 
age, supporting the hypothesis that these cardiorespiratory events essentially represent nonspecific stress 
responses of very low birth weight (VLBW) PIs, whose maturity progresses with chronological age [34-35, 
56-60]. In the study by Anderson et al. the incidence of apnea after the first DTaP-IPV- PCV-Hib vaccination 
was 8.4% in extremely PIs, while there was no reaction following the second dose at 4 months. Infants with 
apnea following the 2-month vaccine displayed significantly lower GA and birth weight. Unfortunately, only 
50% cases with apnea after the first vaccination dose at 2 months were evaluated through a 
cardiorespiratory monitoring after the second dose at 4 months [56]. Similarly, in a prospective study by 
Furck et al. the risk of apnea decreased with increasing GA [57]. In this study the frequency of 
apnea/bradycardia after the first dose of DTaP-IPV-PCV-Hib vaccine in 473 preterm infants with a weight 
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<1500 g was 10.8% [57]. In a retrospective observational study by Flatz-Jequier et al. including 64 very low 
birth weight PIs aged <32 weeks, 33 infants developed a cardiorespiratory event after the first dose of 
DTaP-IPV-Hib vaccination and 6 of them required medical interventions after the second vaccine for a 
similar event, identifying a positive history of previous analogous AE as a significant risk factor for the 
recurrence of a cardiorespiratory event [35]. In the study by Clifford et al. evaluating the frequency of 
apnea and bradycardia up to 48 hours after DTPa-IPV-HBV-Hib-PCV7 and oral rotavirus vaccine at 2 and 4 
months of age, 7 out of 38 preterm infants developed recurrent apnea after vaccination. Lower birth 
weight and ongoing hospitalization for complications related to prematurity increased the risk of a 
recurrent apnea following vaccination [34]. Accordingly, a large multicenter retrospective cohort study by 
De Meo et al. including 13926 extremely PIs showed an increase in the respiratory support need in the 3 
days following vaccination compared with the 3 days preceding the procedure, particularly in infants of 23-
34 weeks of GA compared with older PIs [58]. 
Other studies investigated possible risk factors for post-vaccination apnea other than lower GA, lower birth 
weight, lower chronological age and positive history of previous similar events [59-60]. 
A retrospective cohort study by Hacking et al. including 411 extremely PIs observed a higher incidence of 
apnea in PIs who had previously experienced septicemia and had a greater mean total accumulated time on 
CPAP prior to vaccination [59].  A multivariate analysis by Klein et al. identified age ≤31 weeks of gestation, 
increased initial illness severity scores at birth, birth weight <2 kg and the presence of pre-vaccination 
apnea as independent risk factors for post-vaccination apnea [60]. 
Conversely, the only available randomized blinded controlled multicenter study investigating the incidence 
of apnea in PIs found no increased incidence of post-vaccination apnea[61]. They investigated the 
frequency of cardiorespiratory events after DTaP vaccination at 2 months of age in 191 PIs with a GA<37 
weeks. Infants were randomly assigned to a group that received DTaP vaccine or a control group that did 
not. No significant differences in apnoea or bradycardia frequency were found between the two groups 
[61]. 
A randomized double blinded placebo controlled trial by Ben Jmaa et al. included 56 PIs <32 weeks of 
gestation vaccinated at 2 months of age randomized in two group: the ibuprofen treatment group and the 
placebo group. Ibuprofen treatment significantly attenuated the variation of cardio-respiratory event 
following first vaccine. Authors speculated that the inflammatory processes triggered by vaccine might be 
responsible for the respiratory depression often observed in PIs and suggested a possible protective role of 
ibuprofen [62]. 
 
3.2-Studies on vaccine immunogenicity and efficacy/effectiveness. 
 
Immunogenicity and efficacy/effectiveness was assessed in 22 studies overall including 1,566,350 infants 
(Table 4-5) [31, 41-42, 45- 50, 53-54, 63-72]. 
3.2.1-Studies on live attenuated vaccines’ immunogenicity and efficacy/effectiveness. 
Live attenuated vaccines were investigated in 6 studies [41, 42, 45, 46, 63, 64].   The immunogenicity of the 
early vs. delayed BCG vaccination (BCG at birth vs BCG at 34 weeks gestational age) in moderately preterm 
infants was studied by in-vivo (i.e. Mantoux test and scar formation 6 months after BCG vaccination) and in-
vitro methods (i.e. rise IFN-ɤ after BCG vaccination) by Saroha et al. The overall immunogenicity of BCG in 
this study was 98.3% independently from the time of vaccine administration. [42]. Even Faridi et al. in a 
prospective observational study evaluated the immunogenicity of BCG administered to infants of 31–41 
weeks gestation within 7 days after birth. The 95.8% of enrolled patients had either a reactive Mantoux test 
or positive leukocyte migration inhibition test 6 months after BCG vaccination [63]. 
Ichikawa et al. investigated immunogenicity of anti-measles vaccine at 6 months of age in PIs<34 weeks of 
gestation. Early vaccination at 6 months reached protective antibody titers in all cases 1 month after 
vaccination without a decay during the 12 months after vaccine [41]. 
A prospective study by Ferreira et al. compared the immune response to measles and varicella vaccination 
in infants born prematurely with those born full-term. The proportion of infants with protective humoral 
titers to measles and varicella after vaccination were similar in both groups [64]. 
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Two studies focused on rotavirus vaccine immunogenicity and effectiveness [46, 45]. Omenaca et al. 
assessed immunogenicity of rotavirus vaccine dosing IgA specific antibody 30–83 days post-dose 2 in a 
randomized double blind multicenter controlled trial. Seroconversion rate was 85.7% in the vaccine group 
and 16.0% in the placebo group [46]. Effectiveness of rotavirus vaccination was the topic of the study 
performed by Roué et al. with the aim to evaluate the impact of the pentavalent rotavirus vaccine on the 
number of hospitalizations for rotavirus diarrhoea in preterm infants. A significant decrease in the number 
of hospitalizations for rotavirus infection in infants younger than 3 years of age in the three epidemic 
seasons following the vaccine introduction was found [45]. 
3.2.2-Studies on inactivated or subunit vaccines’ immunogenicity and efficacy/effectiveness. 
Tsuda et al. evaluated the immunogenicity of Hib vaccine in PIs evaluating antibody anti-
polyribosylribitolphosphate (PRP) geometric mean concentrations (GMCs) after the third dose of vaccine. 
The seroconversion rate was lower, but not significantly, in preterm than in full term infants (85.2% vs. 
92.4%) [47]. 
Immunogenicity of pneumococcal vaccine was investigated in 6 studies [31, 49, 54, 65, 66, 67], while the 
assessment of the PCV effectiveness was the aim of one study [68]. Regarding immunogenicity results are 
discordant. Two studies [54,65] reported protected specific antibody levels in high proportion of PIs, 
however several other authors found lower titers, especially against some serotypes such as 6B and 23F 
[31,49]. 
A trial by Omenaca et al. assessed immunogenicity of the PHiD-CV in two groups of preterm infants (those 
born between 27 and 30 weeks vs. those born between 31-36 weeks). At least 93% and 97.6% of infants in 
each group reached protective antibody titers 1 month after primary vaccination and after the booster 
dose respectively, without any difference in antibody titers between groups [54]. Szynczewska et al. 
assessed the concentration of specific IgG against serotypes of PCV7 in 60 PIs [65]. Ninety-one % and 100% 
of patients reached protective antibody concentrations after administration of three doses of the vaccine 
and after the booster dose respectively. Serotypes 6B and 23F were the least immunogenic ones[65]. 
On the other hand, only 36% term infants and 34% PIs achieved protective levels against all PVC7 vaccine 
serotypes following the primary vaccination [31]. Preterm birth adversely affected the GMCs to serotypes 
4, 6B, 14, 19F, and 23F [31]. Immunogenicity of PCV13 was investigated in one RCT by Kent et al. including 
199 PIs <35 weeks of GA, randomized to receive a reduced, accelerated and extended schedule of PCV13 
[49]. Lack of seroprotection toward more than one-half of the PCV13 serotypes was seen in 25%, 12%, and 
3% of participants receiving the reduced, accelerated and extended schedules respectively. Waning of 
pneumococcal antibody concentrations was evident at 12 months of age. Later gestational age was 
associated with an increase in post-primary vaccination IgG concentrations for some serotypes, while 
receipt of antenatal steroids was associated with decreased odds of seroprotection after primary 
vaccination for some serotypes [49]. 
An open-label, multicenter trial by Martinón-Torres et al. evaluated antipneumococcal antibody responses 
elicited by PCV13 with a longer follow up, evaluating specific IgG antibody 1 and 2 years after the fourth 
dose (toddler dose) in PIs compared with term infants. IgG GMCs in both infant groups at the 1-year and 2-
year follow-up visits were lower than GMCs 1 month after the toddler dose for all serotypes. Particularly 
IgG GMCs in PIs were statistically significantly lower at both follow-up time points for serotypes 6B, 18C, 
19A, 19F and 23F, while IgG GMCs for serotypes 5, 6A and 9V were statistically significantly lower in PIs at 
the 1-year follow-up only [67]. 
Despite controversial immunogenicity results the only study investigating antipneumococcal effectiveness 
found reassuring results. Authors assessed the impact of PCV7 on invasive pneumococcal disease (IPD) in 
PIs comparing those born in 2000 (prior to the recommendation to vaccinate with PCV7 preterm infants) 
with those born in 2007. A reduction in notifications of IPD in 2007 was found both in full term and in PIs, 
although this reduction was not significant in the latter. No PIs with reported IPD received full vaccination 
with booster dose according to the recommended schedule. In two IPD cases were both not vaccinated and 
presented with a serotype included in PCV7 [68]. 
Two studies focused on influenza vaccine [48,69]. Esposito et al. evaluated the immunogenicity of influenza 
A/H1N1 MF59-adjuvanted vaccine measuring antibody immediately before administration of dose 1 and 2 
and 4 weeks after the dose 2. GMCs were significantly higher after the second dose and significantly lower 
in PIs <32 weeks of gestation, thus confirming that a very low GA may lead to a reduced immune response. 
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However seroprotection rates were >90% after the first dose in all the groups, suggesting that a single dose 
of vaccine administered after the sixth month of life can protect almost all children aged <23 months [48]. 
Shen et al. examined influenza-related healthcare use outcomes among preterm and full-term children 
aged 6–23 months. The effectiveness of seasonal influenza vaccination was evaluated by examining 
influenza-coded ambulatory visits (physician office and ED visits) during influenza season periods over five 
years in more than 600,000 patients. Full vaccination was associated with an overall 19% reduction in 
ambulatory visits, however a significant reduction was observed only in full term infants [69]. 
Klein et al. investigated the immunogenicity of the primary series of IPV given as part of a combined vaccine 
evaluating poliovirus type 3–specific memory T cell, poliovirus type 3–specific cell-mediated immunity and 
neutralizing antibody response against poliovirus serotypes 1, 2 and 3. Preterm and term infants developed 
comparable mean frequencies of poliovirus-specific memory T cell responses. Considering mononuclear 
cells proliferation (PBMCs), PIs were significantly less likely to have a positive stimulation index (SI) than 
term infants, while all infants had a seroprotective antibody response to all 3 poliovirus serotypes. However 
the GMCs to poliovirus serotype 1 was significantly lower in both the group of all preterm infants [50]. 
Two studies investigated immunogenicity or effectiveness of pertussis vaccination in PIs [70-71]. Vermeulen 
et al. assessed the persistence of the specific immune responses against Bordetella pertussis in three 
groups of one-year old children born prematurely: one group received a whole cell vaccine (Pw) for the 
primary vaccination and a two components acellular vaccine (Pa) as booster dose; the second group 
received  a two component Pa vaccine for every dose of the schedule, the third group received a three 
component Pa vaccine. The antigen specific cellular immune response persisted at year of age, however 
acellular vaccines induced a lower specific Th1 type immune response compared with Pw vaccine [70]. 
Hviid in a large retrospective nationwide Danish study observed a reduced immunogenicity of whole cell 
pertussis vaccine in PIs after the first dose but the completed primary series was equally effective in 
preterm and full-term children [71]. 
Omenaca et al. found an optimal immunogenicity of Hib-MenC-TT vaccine in 309 PIs [53]. In the same study 
anti-HBV IgG levels were also measured as secondary objectives after concomitant coadministration of 
DTaP-HBV-IPV showing a gestational age-related profile, with the lowest levels observed in infants aged 
≤31 weeks.  Similar findings were evident in another study suggesting that PIs have lower humoral response 
to HBV than full-term infants in terms of GMCs but not in term of seroprotection rates[73]. 
 
4-Conclusion 
Our findings are in general reassuring regarding the safety and immunogenicity of vaccines in PIs. Studies 
on BCG, rotavirus and measles vaccination found no increased risk of AEs. Considering inactivated/subunit 
vaccines, pain, redness and swelling in the injection site are frequently reported, as expected. However, 
large injection-site swellings after the booster dose have been reported less frequently in the preterm than 
in full-term infants by some authors [53, 54, 74], but not by others [75-77]. Some authors postulated that a 
reduced immune response in PIs could result in fewer AEs immediately following vaccination [52]. Apnea 
and changes in activity (i.e. drowsiness, irritability and loss of appetite) were other frequently reported 
adverse events [53-55].  Incidence of cardiorespiratory events vary widely (from 1% to 59.1% of PIs) [34-35, 
56-62].  Most cardiorespiratory events resolved spontaneously or required minimal intervention [35]. A 
causal relationship between vaccination and the occurrence of cardiorespiratory events continues to be 
widely debated. This may be due to the lack of a control group in many studies, their retrospective nature, 
sample sizes too small to demonstrate statistically significant differences, the difficulty in distinguishing 
apnea due to vaccination from background instability and the frequent presence of confounding factors 
(i.e.: periventricular hemorrhage, bronchopulmonary dysplasia, history of sepsis during hospitalization). 
Moreover, the incidence of post vaccination apnea could be influenced by the so-called “healthy 
vaccinated” effect, by which clinicians wait until infants are more stable to immunize, thus reducing the 
observed incidence of adverse events. However, the chance of experiencing an apnea after vaccination 
seems to be related with lower GA and birth weight [56, 60], supporting the hypothesis that these 
cardiorespiratory events essentially represent nonspecific stress responses of preterm infants [35,58]. 
Moreover, newborns who experienced apnea after vaccination were those with a previous severe clinical 
condition such as late onset sepsis or requiring long time CPAP support [55, 59]. One important risk factor 
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for recurrence of cardiorespiratory event seems to be a positive history of previous similar adverse 
reaction, particularly in the 24 h prior to vaccine [35, 50, 60, 78]. 
Notably, the only controlled prospective randomized study by Carbone et al. [61] suggested that 
vaccination does not directly contribute to cardiorespiratory events showing no difference in occurrence or 
severity of apnea/bradycardia in vaccine recipients vs. controls. In this study clinical reviewers were blinded 
to vaccination status and study phase (before or after vaccination), but one possible bias of the study could 
be that PIs with unstable vital signs were excluded as were infants who required assisted ventilation. 
In conclusion given the risks of cardio-respiratory events but also the increased risk of VPDs, PIs who are 
still hospitalized at 2 months of age should be vaccinated prior to discharge from hospital and should be 
monitored for 48–72 h after vaccination. This is particularly important in PIs with VLBW with a previous 
history of cardiorespiratory events, especially in the 24 h prior to vaccination. When a cardiorespiratory AE 
to the first dose is suspected, consideration should be given to administering the second vaccination under 
controlled circumstances. 
Considering immunogenicity, the proportion of PIs who developed humoral immunity were generally 
similar in preterm compared with full term infants for many vaccines, with contrasting results for PCV 
vaccines, even if PCV7 effectiveness was found to be high in preterm infants in one study [64, 66, 73]. Good 
seroprotection rate for Hib, MenC, HBV, influenza and IPV vaccinations were reported in PIs [47, 48, 50, 53, 
72], even if lower gestational ages were associated to lower GMCs 
in most of the studies and for most valences (i.e. HBV, Hib, IPV, influenza, pneumococcal and pertussis 
vaccine), suggesting a lower immunogenicity for PIs [31, 48, 50, 53, 67, 73]. 
Even if a possible impairment of Th1 response in PIs has been suggested [79-80], several results of studies 
documented an appropriate cellular immune response toward several vaccines (BCG, pertussis, IPV) [42, 
50, 63, 70].  One study reported imbalance in Th1/Th2 response in recipients of acellular pertussis 
vaccination, depending on the vaccine type, but clinical impact of such a finding is unclear [70]. 
Unfortunately, only 4 studies evaluating vaccine effectiveness (rotavirus, influenza, PCV, and pertussis) 
were retrieved [45,68,69,71].  Notably, all the large population based studies documented no differences in 
vaccine effectiveness between preterm and full term infants. 
Our review presents several limitations: our literature search might have missed some studies. However, 
two authors independently performed literature searches in order to minimize this possibility. The study 
design of the retrieved papers varied and some of them included small datasets, especially for live 
attenuated vaccinations, thus further investigations are required. In addition, data about extreme PIs are 
poor and a distinction of results according to grade of prematurity is not always performed in the studies 
enrolled. 
 
5-Expert opinion 
Neither gestational age nor birth weight should delay the decision to start vaccination in clinically stable 
PIs. Postponing vaccination is justified only in clinically unstable infants. If PIs are still hospitalized at the 
time at which they should be vaccinated they should receive their first vaccine in the neonatal ward 
monitoring them for 48–72 h after vaccination. This is particularly important for infants born ≤31 weeks of 
GA, with birth weight <2 Kg, with pre-vaccination apnea episodes or with severe bronchopulmonary 
dysplasia. Educational programs for health professionals and caregivers should be improved in order to 
avoid delay in vaccination of these infants. 
Most of the available studies comparing the immunogenicity of DTaP-IPV-Hib-HBV and PCV in preterm and 
full term infants apply a 3-dose primary series of vaccination [31, 45, 50, 53-54, 65, 67-71, 73] as 
recommended by the Centers for Disease Control and Prevention [81]. Even if many countries like United 
Kingdom, Australia and Canada adopt a 3-dose primary series, other European countries, including Italy, 
apply a 2+1-dose primary series for hexavalent/pentavalent and pneumococcal vaccination. 
Currently only one study compared different schedules of immunization with PCV13 [49], showing lower 
specific IgG GMCs with the reduced schedule after the primary course but superior antibody concentrations 
after the booster dose in comparison with extended or accelerated schedules. According to some experts’ 
opinions, it could be preferable to vaccinate very PIs with a 3-dose primary series of DTaP-IPV-HBV-Hib and 
PCV. However, further studies are needed in order to better understand the immunogenicity of the 2+1 
schedule in very PIs (< 32 weeks of gestational age). 
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Specific issues should be considered regarding rotavirus vaccination considering the risk of transmission of 
the live attenuated virus in the stool of immunized PIs still hospitalized in NICUs. Several international 
guidelines recommend that rotavirus vaccine should be administered within 6 to 14 weeks and 6 days of 
age in order to minimize the potential risk of intussusception [82,83,84]. Canadian and American guidelines 
suggest rotavirus vaccine administration at or following discharge from the NICUs to prevent the spread of 
vaccine virus in the hospital setting with the risk of missing possible cardiorespiratory events but also the 
risk of missing the benefit of rotavirus vaccination in term of immunogenicity overcoming the specific time 
of administration of vaccine [82-83]. A possible compromise could be policy adopted by British guidelines 
recommending to vaccine PIs still hospitalized applying routine standard infection control precautions [84]. 
Further studies are needed to develop evidence-based recommendations regarding the necessity to 
monitor PIs with suspected cardio-respiratory event following the first vaccine when the second 
immunisation is performed, considering also direct and indirect costs of a prolonged hospitalization. 
 
Although several studies have been retrieved, limited data are available regarding vaccine effectiveness in 
preterm infants, particularly after the schedule 2+1 for the hexavalent vaccine and PCVs. Therefore, further 
studies are needed in this respect, especially focusing on the more recently marketed vaccines (i.e. PCV13 
and anti-meningococcal vaccines) and on the need for eventual additional booster doses. Moreover, future 
studies should analyse the potential differences between subgroups of preterm infants, such as extremely 
preterm ones (<29 weeks gestational age) to assess whether they need additional vaccine or earlier booster 
doses. 
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Table and figure legends 
Table 1: PRISMA 2009 Checklist filled out [40]. 
Table 2: Sixty-one articles identified with the search details (infant, preterm"[MeSH Terms]) AND 
"vaccination"[MeSH terms] and exclusion criteria for the screening relying on studies’ abstracts or titles. 
 
Table 3: Studies regarding vaccine safety in preterm infants. 
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Information Classification: General 
[Notes: DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral 
polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent 
antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus 
influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-
CV =PCV10-non typeable H.influenzae protein D conjugate vaccine; SNAP-II: Score for Neonatal Acute 
Physiology II (SNAP-II); AOR=adjusted odd ratio; CI=confidence interval]. 
 
Table 4: Studies regarding vaccine immunogenicity in preterm infants 
[Notes: DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral 
polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent 
antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus 
influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-
CV =PCV10-non typeable H. influenzae protein D conjugate vaccine; FHA=filamentous haemagglutinin; 
PT=pertussis toxin; PRN=pertactin; OPA=opsonophagocytic activity; SNAP-II: Score for Neonatal Acute 
Physiology II (SNAP-II), MMR=measles, mumps, and rubella vaccine; GMCs= geometric mean 
concentrations; PRP= anti-polyribosylribitolphosphate; IPD= invasive pneumococcal disease; 
LMIT=leukocyte migration inhibition test; SBAMenC=seroprotective serum bactericidal activity thresholds 
against meningococcal serogroup C vaccine]. 
 
Table 5: Studies regarding vaccine effectiveness in preterm infants. 
[Notes: DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral 
polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent 
antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus 
influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-
CV =PCV10-non typeable H. influenzae protein D conjugate vaccine; SNAP-II: Score for Neonatal Acute 
Physiology II (SNAP-II), MMR=measles, mumps, and rubella vaccine; GMCs= geometric mean 
concentrations; PRP= anti-polyribosylribitolphosphate; IPD= invasive pneumococcal disease; 
LMIT=leukocyte migration inhibition test, IC=interval confidence; ED=emergency department; HR= Adjusted 
hazard ratios; Pw=pertussis whole vaccine; Pa=pertussis acellular vaccine]. 
 
Figure 1: Four-phase flow diagram of the systematic review in accordance with PRISMA guidelines [40]. 
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Information Classification: General 
Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration 
number.  
1 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
1 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
2 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
Not 
applicable 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
3 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
3 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
3 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
3 
Table 2 
Figure 1 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
3 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
3 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at 
the study or outcome level), and how this information is to be 
used in any data synthesis.  
3 
Table 3-5 
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Information Classification: General 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
Not 
applicable 
Synthesis of 
results  
14 Describe the methods of handling data and combining results 
of studies, if done, including measures of consistency (e.g., 
I2) for each meta-analysis.  
Not 
applicable 
 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
3 
Table 3-5 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
Not 
applicable 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
3-4 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
4-13 
Table 3-5 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
4-13 
Table 3-5 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally 
with a forest plot.  
Table 3-5 
Synthesis of 
results  
21 Present the main results of the review. If meta-analyses are 
done, include for each, confidence intervals and measures of 
consistency" in accordance with the text in the Explanation 
and Elaboration document. 
Not 
applicable 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
Table 3-5 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity 
or subgroup analyses, meta-regression [see Item 16]).  
Not 
applicable 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
13-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
15 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
15-16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
16 
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Information Classification: General 
systematic review.  
 
Table 1: PRISMA 2009 Checklist filled out [40].  
 
 
References Excluded/ 
included 
Reason 
Omeñaca F, Vázquez L, Garcia-Corbeira P, Mesaros N, Hanssens L et al. 
Immunization of preterm infants with GSK's hexavalent combined 
diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-
Haemophilus influenzae type b conjugate vaccine: A review of safety and 
immunogenicity.Vaccine.2018;36:986-96. 
Excluded Review 
Ferreira CSM, Perin MCAA, Moraes-Pinto MI, Simão-Gurge RM, Goulart 
AL et al. Humoral immune response to measles and varicella vaccination in 
former very low birth weight preterm infants. Braz J Infect Dis.2018;22:41-6. 
[64] 
Included  
(immunogenicity) 
 
Sisson H, Gardiner E, Watson R. Vaccination timeliness in preterm infants: 
An integrative review of the literature. J Clin Nurs.2017:26;4094-104. 
Excluded Review 
Cuna A, Winter L. Quality Improvement Project to Reduce Delayed 
Vaccinations in Preterm Infants. Adv Neonatal Care.2017;17:245-49. 
Excluded Not pertinent 
Wilińska M, Warakomska M, Głuszczak-Idziakowska E, Jackowska T. Risk 
factors for adverse events after vaccinations performed during the initial 
hospitalization of infants born prematurely. Dev Period Med.2016;20:296-
305. [55[ 
Included 
(safety) 
 
Martinón-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanislawska E, 
et al. Circulating Antibody 1 and 2 Years After Vaccination With the 13-
Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term 
Infants. Pediatr Infect Dis J.2017;36:326-32. [67] 
Included 
(immunogenicity) 
 
Kucukoglu S, Aytekin A, Celebioglu A, Celebi A, Caner I, et al. Effect of 
White Noise in Relieving Vaccination Pain in Premature Infants. Pain Manag 
Nurs.2016;17:392-400. 
Excluded Not pertinent 
Kent A, Ladhani SN, Andrews NJ, Scorrer T, Pollard AJ, et al. Schedules for 
Pneumococcal Vaccination of Preterm Infants: An RCT. 
Pediatrics.2016;138:e20153945-58[49] 
Included 
(immunogenicity 
and safety) 
 
Kilich E, Sadarangani M. Use of rotavirus vaccines in preterm babies on the 
neonatal unit. Expert Rev Vaccines.2016;15:1463-65. 
Excluded Not pertinent 
Kjærgaard J, Stensballe LG, Birk NM, Nissen TN, Thøstesen LM, et al. 
Bacillus Calmette-Guérin vaccination at birth: Effects on infant growth. A 
randomized clinical trial. Early Hum Dev.2016;100:49-54 [43] 
Included 
(safety) 
 
Higgins RD, Shankaran S. The Neonatal Research Network: History since 
2003, future directions and challenges. Semin Perinatol.2016;40:337-40. 
Excluded Not pertinent 
Olsen SJ, Mirza SA, Vonglokham P, Khanthamaly V, Chitry B et al. The 
Effect of Influenza Vaccination on Birth Outcomes in a Cohort of Pregnant 
Women in Lao PDR, 2014-2015. Clin Infect Dis.2016;63:487-94. 
Excluded Not pertinent 
Kjærgaard J, Stensballe LG, Birk NM, Nissen TN, Foss KT et al. Lack of a 
Negative Effect of BCG-Vaccination on Child Psychomotor Development: 
Results from the Danish Calmette Study - A Randomised Clinical Trial. 
PLoS One.2016;11:e0154541. [44] 
Included 
(safety) 
 
Navarro-Alonso JA, Taboada-Rodríguez JA, Limia-Sánchez A; Toward a 
New Immunization Schedule in Spain, 2016 (Part 2). Rev Esp Salud 
Publica.2016;90:E3. 
Excluded Review 
McArdle AJ, Mugisha G, Birahinduka D. QUESTION 2: Vaccinating 
preterm infants in resource-poor settings: what is the incidence of apnoea, 
bradycardia and need for respiratory support? Arch Dis Child 2016;101:290-
3. 
Excluded Commentary 
Salamouras D, Levy J. Vaccination of premature infants, a population at high 
risk of infection. Rev Med Brux.2015;36:223-8 
Excluded Review in French 
Saroha M, Faridi MM, Batra P, Kaur I, Dewan DK. Immunogenicity and 
safety of early vs delayed BCG vaccination in moderately preterm (31-33 
weeks) infants. Hum Vaccin Immunother.2015;11:2864-71 [42] 
Included  
(safety and 
immunogenicity) 
 
McCrossan P, McCafferty C, Murphy C, Murphy J. Retrospective review of 
administration of childhood primary vaccination schedule in an Irish tertiary 
neonatal intensive care unit. Public Health.2015;129:896-8. 
Included  
(safety) 
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Information Classification: General 
Kilich E, Anthony M. Rotavirus vaccination in preterm infants: a neonatal 
guidance chart to aid timely immunisation. Arch Dis Child Fetal Neonatal 
Ed.2015;100:F465. 
Excluded Letter 
Mehler K, Ulbrich L, Börner S, Joachim A, Becker I, et al. Multidimensional 
response to vaccination pain in very preterm, moderate- to-late preterm and 
full-term infants at age three months. Early Hum Dev.2015;91:199-204 
Excluded Not pertinet 
Ochoa TJ, Zea-Vera A, Bautista R, Davila C, Salazar JA et al. Vaccine 
schedule compliance among very low birth weight infants in Lima, Peru. 
Vaccine.2015;33:354-8. 
Excluded Not pertinent 
Czajka H, Lauterbach R, Pawlik D. Vaccination of preterm infants by 
polyvalent vaccines: immunogenicity and safety- review of literature. Dev 
Period Med.2014;18:360-6 
Excluded Review 
Erener-Ercan T, Aslan M, Vural M, Erginoz E, Kocazeybek B et al. Tetanus 
and diphtheria immunity among term and preterm infant-mother pairs in 
Turkey, a country where maternal and neonatal tetanus have recently been 
eliminated. Eur J Pediatr.2014;174:339-44 
Excluded Not pertinent 
Tozzi AE, Piga S, Corchia C, Di Lallo D, Carnielli V et al. Timeliness of 
routine immunization in a population-based Italian cohort of very preterm 
infants: results of the ACTION follow-up project. Vaccine.2014;32:793-9. 
Excluded Not pertinent 
Woestenberg PJ, van Lier A, van der Maas NA, Drijfhout IH, Oomen PJ et al. 
Delayed start of diphtheria, tetanus, acellular pertussis and inactivated polio 
vaccination in preterm and low birth weight infants in the Netherlands. 
Pediatr Infect Dis J.2014;33:190-8. 
Excluded Not pertinent 
Szynczewska E, Chlebna-Sokół D. Immunogenicity of heptavalent conjugate 
vaccine against Streptococcus pneumoniae in premature babies with low birth 
weight. Pediatr Neonatol.2014 Apr;55(2):101-7 [65] 
Included 
(immunogenicity) 
 
Shen S, Campitelli MA, Calzavara A, Guttmann A, Kwong JC. Seasonal 
influenza vaccine effectiveness in pre- and full-term children aged 6-23 
months over multiple seasons. Vaccine.2013;31:2974-8 [69] 
Included 
(effectiveness) 
 
Wilson K, Hawken S, Holdt Henningsen K, Kwong JC, Deeks SL et al. On-
time vaccination coverage in premature infants in Ontario, 2002-2009. Can J 
Public Health.2012;10:e359-62 
Excluded Not pertinent 
Vermeulen F, Dirix V, Verscheure V, Damis E, Vermeylen D, et al. 
Persistence at one year of age of antigen-induced cellular immune responses 
in preterm infants vaccinated against whooping cough: comparison of three 
different vaccines and effect of a booster dose. Vaccine.2013;31:1981-6 [70] 
Included 
(immunogenicity) 
 
Ichikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early 
measles vaccination (AIK-C strain) for preterm infants. Pediatr 
Int.2013;55:163-8. 
Included (safety 
and 
immunogenicity) 
 
Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability 
of vaccinations in premature infants. Expert Rev Vaccines.2012;11:1199-
209. 
Excluded Review 
Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for 
exposure misclassification using survival analysis with a time-varying 
exposure. Ann Epidemiol.2012 ;22:799-806 
Excluded Not pertinent 
Wilson K, Hawken S. Incidence of adverse events in premature children 
following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] 
Included (safety)  
Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center 
matching study on antibody response between preterm and full-term infants 
after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing 
Xue Za Zhi.2012;33:185-8. 
Excluded Not written in 
english 
Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse 
cardiorespiratory events following primary vaccination of very low birth 
weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 
Excluded Not written in 
english 
Gaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm 
infant. Rev Prat.2012;62:382-3 
Excluded Not written in 
english 
Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A 
(H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. 
Vaccine.2012 Mar 30;30(16):2671-5. 
Excluded Not pertinent 
Buijs SC, Boersma B. Cardiorespiratory events after first immunization in 
premature infants: a prospective cohort study]. Ned Tijdschr 
Geneeskd.2012;156:A3797. 
Excluded Not written in 
english 
Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. 
Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in 
preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis 
J.2012;31:487-93 
Included (safety 
and 
immunogenicity) 
 
Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune 
response to Haemophilus influenzae type b conjugate vaccine in preterm 
infants. Pediatr Int. 2012;54:64-7 [47] 
Included (safety 
and 
immunogenicity) 
 
Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lower 
respiratory disease and vaccination of premature infants. 
Excluded Not pertinent 
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Information Classification: General 
Vaccine.2011;29:7611-7  
Omeñaca F, Arístegui J, Tejedor JC, Moreno-Perez D, Ruiz-Contreras J et al. 
Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup 
C vaccine is immunogenic and well tolerated in preterm infants when 
coadministered with other routinely recommended vaccines. Pediatr Infect 
Dis J.2011;30:e216-24 [53] 
Included (safety 
and 
immunogenicity) 
 
Omeñaca F, Merino JM, Tejedor JC, Constantopoulos A, Papaevangelou V, 
Kafetzis D. Immunization of preterm infants with 10-valent pneumococcal 
conjugate vaccine. Pediatrics 2011;128:e290-8 [54] 
Included (safety 
and 
immunogenicity) 
 
Calderón C G, Moore V R, Pittaluga P E, Potin S M. Adherence to 
immunizations in newborns less than 1500 gr at birth and/or younger than 32 
weeks, in two chilean centers. Rev Chilena Infectol.2011;28:166-73 
Excluded Not written in 
english 
Clifford V, Crawford NW, Royle J, Lazzaro T, Danchin M, et al. Recurrent 
apnoea post immunisation: Informing re-immunisation policy. 
Vaccine.2011;29:5681-7. [33] 
Included (safety)  
Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A et al. Influenza 
A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 
months. Pediatrics.2011 May;127:e1161-8. [48] 
Included (safety 
and 
immunogenicity) 
 
Zanoni G, Gottin L, Boner A, Piacentini G, Peroni D et al. Case discussion of 
an immediate serious reaction to hexavalent vaccine mistaken for 
anaphylaxis. Br J Clin Pharmacol.2010;70:916-7. 
Excluded Case report 
Mirpuri J, Jain L. Issues of prematurity and HIV infection. Clin 
Perinatol.2010;37:887-905 
Excluded Not pertinent 
Baxter D. Premature infants and vaccination. Hum Vaccin.2010;6:493. Excluded Comment on 
Trück J, Pollard AJ. Challenges in immunisation against bacterial infection in 
children. Early Hum Dev.2010;86:695-701. 
Excluded Not pertinent 
Dhillon S. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa). 
BioDrugs.2010;24:299-302 
Excluded Review 
Baxter D. Vaccine responsiveness in premature infants. Hum 
Vaccin.2010;6:506-11 
Excluded Review 
Baxter D. Impaired functioning of immune defenses to infection in premature 
and term infants and their implications for vaccination. Hum 
Vaccin.2010;6:494-505. 
Excluded Review 
Tinnion RJ, Berrington JE. Flu vaccination for ex-preterms and infants under 
6 months--are we getting it right? Arch Dis Child.2010 May;95:400-1 
Excluded Letter 
Baxter D, Ghebrehewet S, Welfare W, Ding DC. Vaccinating premature 
infants in a Special Care Baby Unit in the UK: results of a prospective, non-
inferiority based, pragmatic case series study. Hum Vaccin.2010;6:512-20. 
Included 
(immunogenicity) 
 
Pinquier D, Adde-Michela C, Ploin D, Levêque C, Marret S; Vaccination rate 
of premature infants at 6 and 24 months of age: a pilot study. Arch 
Pediatr.2009 Dec;16:1533-9. 
Excluded Not written in 
english 
Esposito S, Serra D, Gualtieri L, Cesati L, Principi N. Vaccines and preterm 
neonates: why, when, and with what. Early Hum Dev 2009;85:S43-5. 
Excluded  Review 
Fleischer L, Syed SS. Hepatitis B surface antigenemia in a neonate following 
vaccination with Pediarix. Clin Pediatr.2009;4:311-2. 
Excluded Case report 
Ryan MA, Gumbs GR, Conlin AM, Sevick CJ, Jacobson IG et al. Evaluation 
of preterm births and birth defects in liveborn infants of US military women 
who received smallpox vaccine. Birth Defects Res A Clin Mol 
Teratol.2008;82:533-9 
Excluded Not pertinent 
Klein NP, Massolo ML, Greene J, Dekker CL, Black S et al. Risk factors for 
developing apnea after immunization in the neonatal intensive care unit. 
Pediatrics.2008;121:463-9 [60] 
Included (safety)  
Table 2: Sixty-one articles identified with the search details (infant, preterm"[MeSH Terms]) AND 
"vaccination"[MeSH terms] and exclusion criteria for the screening relying on studies’ abstracts or titles.  
 
 
Author 
(year) 
Design No of pts Gestatio
nal Age 
in 
weeks 
(w) 
Location Vaccine Objectives Follow 
up (FU) 
after 
vaccine 
Results Bias 
Ben Jmaa 
et al. 
(2017) 62 
Prospective 
randomized, 
double 
blinded, 
placebo-
controlled 
56 < 32 w  Canada DTPa,IPV, 
Hib, 
PCV10 
To analyze cardio-
respiratory Events (CREs) 
48 hours after vaccination 
and inflammatory 
eesponse after primary 
Immunization  
48 h  -Significant correlation between Δ C-
reactive protein and Δ Total 
CRE/patient/24 hours; 
-CRE/patient/24 hours was 
unchanged before versus after 
immunization (6.7 ± 7.7 before 
versus 6.8 ± 9.7 after, P = 0.9) in the 
ibuprofen group 
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Information Classification: General 
Kjærgaard 
et al. 
(2016) 43 
Prospective 
randomized, 
multicenter 
clinical trial 
4262  
(144 born 
32-37 w) 
32-37 w Denmark BCG Effects of BCG 
vaccination on early 
childhood infections, 
growth and development 
in term and preterm infant   
22 
months 
There was no effect of BCG on 
either incidence of infections, 
growth, body composition or 
psychomotor development 
 
Kjærgaard 
et al. 
(2016) 44 
Prospective 
randomized, 
multicenter 
clinical trial 
4262  
(144 born 
32-37 w) 
32-37 w Denmark BCG To assess the non-specific 
effect of Bacillus 
Calmette-Guérin (BCG) 
vaccination at birth on 
psychomotor development  
22 
months 
Lack of a Negative Effect of BCG-
Vaccination on Child Psychomotor 
Development 
 
Kent et al 
(2016) 49 
Phase IV, 
open-label, 
prospective, 
multicenter, 
randomized 
controlled 
trial 
199 <35 w UK PCV13 in 
association 
with other 
polyvalent 
vaccines 
To evaluate solicited 
adverse events (AEs)  
28 days - no significant differences in the 
frequency or severity of local and 
systemic AEs between vaccination 
schedules at any time point 
- 77 serious AEs, of which 1 
possibly related to vaccination 
unexpected serious adverse reaction 
from each randomized group 
 
Wilińska et 
al (2016) 55 
Observational 
prospective  
138  73 ≤ 28 
w 
65 >28  
w  
Poland DTPa-IPV-
HBV-Hib-
PCV 
To assess incidence of 
adverse events following 
vaccination (AEFV) 
monitoring cardio-
respiratory functions and 
body temperature  
72 hours - Apnea and activity dysfunctions 
were the relatively most frequent 
AEFI. 
-Preterm newborns who experienced 
apnea show significantly more 
frequent late onset sepsis (p=0.028) 
as well as a history of longer use of 
continuous positive air pressure 
(CPAP) (p=0.033) 
-no control 
group  
-small 
sample size 
De Meo et 
al (2015) 58 
Multicenter 
retrospective 
cohort study 
13,926 ≤28 w USA DTPa, 
IPV, HBV, 
Hib, PCV7 
To assess sepsis evaluation 
(collection of blood 
culture), need of increased 
respiratory support, 
seizures and death in the 3 
days following vaccination 
3 days -The incidence of sepsis evaluation 
and increased respiratory support 
increa e from the pre-immunization 
period to the post-immunization 
period 
-Infants 23–24 weeks of gestation 
demonstrated an increased incidence 
of sepsis evaluation and increased 
respiratory support compared to 
older infants (27– 28 weeks 
gestation) 
-A prior history of gram-positive 
sepsis was associated with an 
increased rate for sepsis evaluation in 
the post-immunization period. 
-There was no difference in the 
incidence of adverse events in 
combination vaccines versus single-
dose vaccines. 
-“healthy 
vaccinated
”effect  
-physicians 
may be 
more likely 
to 
document 
adverse 
events that 
are 
occurring 
in close 
proximity 
to the 
administrat
ion of 
immunizati
ons 
McCrossan 
et al (2015) 
51 
Retrospective  344 <37 w Ireland DTPa, 
IPV, HBV, 
PCV, Hib 
To assess delay in 
administration and safety 
of vaccines in preterm 
 None of the patients had a 
documented adverse reaction 
-
Retrospecti
ve study 
-not clear 
the period 
of follow 
up 
Saroha et al 
(2015) 42 
Prospective 
randomized 
comparative 
trial 
117 31-33 w India BCG To compare complications 
of BCG vaccine in preterm 
infants aged 31–33 weeks 
immunized at birth or at 
34 completed weeks 
6 
months 
-Left axillary lymphadenopathy was 
the only complication seen in 3.4% 
of patients in in both groups 
-BCG vaccine may be safely given to 
moderately preterm infants (31–33 
weeks) at birth 
 
Roué et al 
(2014) 45 
Population-
based study 
7150 6883>37
w 
 
267<37
w  
France Rotavirus 
vaccine 
To analyze the cause of 
hospitalizations for up to 
42 days after the last dose 
of Rotavirus vaccine  
 
42 days -No significant differences in severe 
AEs following vaccination between 
premature and term infants were 
found (5.2% versus 8.1%, p = 0.09) . 
-No case of intussusception nor of 
Kawasaki disease were reported. 
 
Ichikawa et 
al (2013) 41 
Prospective  17 <34 w Japan Measles 
vaccine 
To evaluate 
immunogenicity and 
safety of early vaccination 
with measles vaccine at 6 
months. 
12 
months 
after 
birth 
AEs did not occur Small 
sample 
Anderson 
et al (2012) 
56 
Retrospective  203 ≤28 w Australia DTaP, 
IPV, Hib, 
PCV 
To evaluate likely/possible 
apneic reaction within 48 
hours following 2 months 
vaccination 
48 h -18 preterm infants had a vaccine 
reaction, 17 with likely/possible 
apnea reaction (incidence 8,4%) after 
2 months vaccination  
-Babies reacting to the 2-month 
vaccine were statistically of lower 
birth gestation and birth weight 
- There were no reactions to the 
following vaccine doses 
-Small case 
numbers 
-lack of 
cardiorespi
ratory 
monitoring 
for the 4-
month 
immunizati
ons in 
approximat
ely 50% of 
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cases 
Omenaca et 
al (2012) 46 
randomized 
double 
blinded 
placebo-
controlled 
trial 
250 ≥27 and  
<37 w 
France, 
Portugal, 
Poland, 
Spain 
Rotavirus 
vaccine  
To assess the occurrence 
of any solicited and 
unsolicited AEs during the 
15- and 31-day 
postvaccination follow-up 
period after each dose, 
respectively and severe 
adverse event (SAE)  
31 days - Frequency of AEs recorded in the 
vaccine and placebo groups were 
similar (P = 0.266). 
-During the 31-day postvaccination 
follow-up period, at least 1 
unsolicited AE was reported in 196 
(29.3%, 95% CI: 25.8–32.9%) and 
138 (40.7%, 95% CI: 35.4–46.1%) 
infants in the vaccine and placebo 
groups, respectively (P < 0.05). 
- The percentage of all and grade 3 
solicited general AEs recorded 
during the 15-day postvaccination 
follow-up period were similar in both 
groups (P > 0.05) with irritability 
being the most common AE reported 
-
coadminist
ration of 
other 
polyvalent 
vaccines 
Tsuda et al 
(2012) 47 
prospective 
cohort study  
54 preterm 
infants 
<37 w Japan Hib To assess immunogenicity 
and side-effects after 
vaccination  
 -Side-effects after vaccination were 
rare, with only one case of local 
redness 
-small 
number of 
samples 
-not clear 
the follow 
up period 
Wilson et al 
(2012) 52 
 
 
Retrospective 
self-
controlled 
case-series 
 
771453 -49220 
born 33-
36 w 
 
-7392 
born ≤ 
32 w 
Canada DTPa-IPV-
HiB-PCV  
 
-to evaluate rates of 
emergency room visits and 
hospital admissions within 
3 days following 2 months 
vaccination  
3 days -Reduced AEs (as emergency room 
visits and hospital admission) were 
observed in preterm infants when 
compared to small for gestational age 
term children. When compared with 
all term children this decrease in risk 
was not statistically significant. 
-the 
healthy 
vaccine 
effect 
-
emergency 
room visits 
and 
hospital 
admissions 
within 3 
days 
following 
vaccination 
could not 
be related 
to 
vaccination 
Clifford V 
et al (2011) 
34 
Observational 
retrospective  
46  -38 born 
< 37 w 
 
-8 born 
≥37 w 
Australia DTPa-IPV-
HBV-
HiB+PCV7 
and 
rotavirus 
vaccine 
 
-To determine recurrence 
rates for AEs following 2 
or 4 month immunisations 
over 48 hours after 
vaccination.  
-To explore potential risk 
factors for recurrence of 
apnea 
48 hours -35/38 preterm infants had an apnoea 
following their 2-month vaccine, 
3/38 had an apnea after their 4-
month vaccine 
-7/38 (18%) preterm infants had 
recurrent apnoea  
-Lower birth weight (p = 0.04) and 
ongoing hospitalisation for 
complications relating to prematurity 
(p = 0.01) increased the odds of a 
recurrent apnoea AEFI.  
- No infant with recurrent apnoea at 
4-months suffered a third apnoea 
AEFI at their 6-month 
immunisations 
-small 
sample size 
-
overestima
tion of the 
number of 
infants 
with a first 
apnoea 
AEFI 
maybe 
because of 
the 
retrospecti
ve nature 
of the 
study 
without the 
possibility 
to confirm 
the 
apnoea 
diagnosis 
Esposito et 
al. (2011) 
48 
Prospective, 
randomized 
open trial  
101 -34 born 
<32 w  
-35 born 
32-36 w 
-32 born  
≥37 w 
Italy Influenza 
A/H1N1 
MF59-
adjuvanted 
vaccine 
 
To assess immunogenicity, 
safety and tolerability of 
influenza A/H1N1 MF59-
adjuvanted vaccine in 
preterm and term children 
aged 6 to 23 months 
14 days -The incidence of local AEs was 2,9-
3,1% in all children  
-The only systemic AE consistently 
recorded was fever, more frequently 
after the first dose than after the 
second dose in all the 
groups(P<0.05) 
 -None of the enrolled children 
experienced any severe AE. 
 
Omeñaca et 
al (2011) 53 
open, 
controlled 
prospective 
multicenter 
study  
313 -56 born 
<31w 
-107 
born 31-
36 w 
 
-150 full 
term 
 
Spain Hib-MenC-
TT  
To assess immunogenicity 
and safety profile in 
preterm infants compared 
with full-term born 
infants. 
To record specific local 
and general solicited 
adverse events for 4 days 
after each vaccination and 
31 days -solicited local symptoms tended to 
be lower than those observed after 
DTPa-HBV-IPV-PCV7  
-Grade 3 local symptoms were 
reported by no more than 7.6% 
-No evidence of increasing 
reactogenicity with an increasing 
number of doses in any group. 
-Grade 3 general symptoms were 
-open 
design 
-no 
randomizat
ion 
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to record unsolicited 
adverse events for 31 days 
after vaccination 
reported by no more than 9.3% and 
2.8% of patients after primary 
vaccination and after the booster 
dose respectively 
Omeñaca et 
al(2011) 54 
Prospective 
clinical trial  
286 -50 born  
27-30 w 
 
-87 born 
31-36 w 
 
-149 full 
term 
Spain, 
Greece 
PHID-CV To evaluate 
immunogenicity and 
safety to PHiD-CV and 
coadministered vaccine at 
2-4-6 month of age, 
followed by a booster dose 
at 16-18 months of age. 
To evaluate local and 
general adverse events for 
4 days after each vaccine 
dose and unsolicited 
adverse events for 31 days 
after vaccine and serious 
adverse events for 6 
months after booster 
vaccination.  
6 
months 
-The most frequently reported 
solicited general AE were irritability, 
drowsiness, fever and loss of 
appetite, but the incidence of high 
grade of general AE was low (i.e. 
0,8-1,5% incidence of fever > 39°C 
within 4 days after each of the 
vaccine doses, 7.1% after the booster 
dose) 
-Incidence of grade 3 solicited local 
AEs was low in both groups, but 
higher after booster vaccination in 
the term group.  
-SAEs were reported but no one 
were considered as causally related 
to vaccination 
- One episode of apnea was reported 
in a preterm infant after the first 
primary dose but was not considered 
to be related to study vaccination and 
resolved without sequelae. 
 
Furck et al 
(2010) 57 
prospective 
observational 
trial 
473 <37 w Germany DTPa, Hib, 
HBV, IPV, 
PCV7 
To assess AEs for up to 
48h following vaccination 
48 hours -The frequency of side effects was 
10.8% and 2.8 % for 
apnea/bradycardia and local 
reaction/fever respectively 
-The chance of suffering from apnea 
decreased with increasing gestational 
week at birth 
-Fever was significantly more 
frequent in infants with cerebral 
hemorrhage grade 3–4 or with 
periventricular leukomalacia (OR 8,7 
and 8,2 respectively) 
-The 3 
groups did 
not have 
the same 
number of 
infants  
-the 
gestational 
age as the 
time of 
vaccination 
decreased 
over the 
years 
Hacking et 
al. (2010) 
59 
Retrospective 
historical 
cohort study 
411 27 w  Australia DTPa, Hib, 
HBV, 
OPV/IPV, 
PCV7 
To evaluate initiation of 
respiratory support 
(CPAP) or intermittent 
positive pressure 
ventilation (IPPV) within 
7 days of the 2-month 
scheduled vaccination 
7 days -22 preterm infants experienced 
some respiratory deterioration in the 
first 3 day after vaccination 
attributed solely to the immunization 
-infants requiring respiratory support 
following vaccination had a higher 
incidence of previous septicaemia (p 
= 0.02) and had a greater mean total 
accumulated time on CPAP prior to 
receiving immunizations (p=0.03) 
-
retrospecti
ve nature 
of the 
study  
cannot 
suggest 
that 
immunizati
on was a 
causative 
factor 
Klein et al 
(2010) 50 
open-label 
prospective 
study, self-
controlled 
case series 
approach 
83 -33 born 
<37w 
 
-50 
born≥37 
w 
USA DTPa, Hib, 
HBV, IPV, 
PCV 
to describe potential 
vaccine-related AEs 
during the 30 days after 
each of 3 doses comparing 
the frequency of these 
events in preterm and term 
infants 
30 days -No AEs like fever, seizure, or 
swelling were reported for either 
preterm or term infants 
-Self-controlled case series analyses 
showed no increase in AEs among 
preterm and term infants after any 
vaccine dose 
Small 
sample size 
Carbone et 
al. (2008) 
61 
Randomized, 
controlled, 
blinded 
multicenter 
study 
197 < 37 w USA DTPa To evaluate increase in 
cardiorespiratory events 
after DTPa in preterm 
infants 
48 hours Absence of increase in 
cardiorespiratory events in DTaP 
group versus the control group 
no long-
term 
observatio
n of the 
untreated 
control 
group. 
Flatz-
Jequier et al 
(2008) 35 
Retrospective 
study 
64 <32 w Switzerlan
d 
DTPa-
IPV/HIB/-
PCV/anti 
VRS 
To evaluate occurrence of 
cardiorespiratory events 
after first 
DTPw or DTPa 
immunization in VLBW 
during the first 48 hours 
after second dose of 
vaccine 
48 hours -33/64 showed significant 
cardiorespiratory event after the 2 
months vaccine. 
-6/33 require medical intervention 
(i.e. oxygen supplementation through 
nasal cannula in 4 patients, tactile 
stimulation in 1 patients, mask 
ventilation in 1 patients) after the 4 
months vaccine 
-None showed significant 
cardiorespiratory event after the third 
vaccine 
-A previous AE to vaccine was a risk 
factors for recurrence of 
cardiorespiratory events. 
-
retrospecti
ve study 
Klein et al. 
(2008) 60 
Retrospective 
study 
497 456 born 
≤30 w 
USA DTPa-IPV-
HBV-Hib-
To assess factors 
associated with 
48 hours - 95% episodes of postimmunization 
apnea (62 of 65 episodes) occurred 
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41 born 
31-41 w 
PCV postimmunization apnea among infants born at ≤31 weeks of 
gestation 
-Bivariate analysis revealed that 
postimmunization apnea was 
markedly associated with the 
presence of preimmunization apnea 
(P < 0.0001) 
- Multivariate analysis conducted 
exclusively among infants without 
apnea before immunization similarly 
found that SNAP-II >10 (AOR: 4.2; 
95% CI: 1.2–14.3), chronological 
age of <67 days (AOR: 2.3; 95% CI: 
1.1–4.8)and weight of <2 kg (AOR: 
2.1; 95% CI: 1–4.5) were associated 
with postimmunization apnea.  
 
Table 3. Studies regarding vaccine safety in preterm infants [Notes: DTaP=diphtheria, tetanus, 
acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral polio vaccine; 
HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent 
antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= 
Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille 
Calmette-Guérin vaccine; PHID-CV =PCV10-non typeable H.influenzae protein D conjugate 
vaccine; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II); AOR=adjusted odd ratio; 
CI=confidence interval]. 
 
 
 
 
 
Study (year) Design No of pts Gestational 
Age in weeks 
(w) 
Location Vaccination Objectives Results Bias 
Ferreira et al. 
(2018) 64 
Prospective 
study 
121 
-65 preterm infants  
-56 full-term infants  
25–34.4 w Brazil  MMR to compare the 
immune response to 
measles and varicella 
vaccination in infants 
born prematurely 
with those born at 
full-term measuring 
measles antibodies at 
12 and 15 months 
(before and after 
MMR vaccine) and 
varicella antibodies at 
15 and 18 months 
(before and after 
vaccine) 
- The percentages of infants with 
humoral immunity to measles 
and varicella after vaccination 
were similar in both groups 
- antenatal corticosteroid use 
reduced the level of measles 
antibodies (p = 0.009), while 
breastfeeding for more than six 
months increased antibody levels 
after varicella vaccination (p = 
0.023). 
 
Martinón-
Torres et al. 
(2017) 67 
open-label, 2-
arm, 
multicenter, 
parallel-group 
study 
 
 
200 
-100 full term infants 
-100 preterm infants 
-25 born <29 w 
-50 born 29–31 
w 
-25 born 32–36 
w 
Spain and 
Poland 
PCV13 To evaluate 
antipneumococcal 
antibody responses 
elicited by PCV13 1 
and 2 years after the 
fourth dose (toddler 
dose) in formerly 
preterm infants 
compared with term 
infants 
-IgG GMCs in both infant groups 
at the 1-year and 2-year follow-up 
visits were lower than GMCs 1 
month after the toddler dose for 
all serotypes. 
-Compared with term infants, IgG 
GMCs in preterm infants were 
statistically significantly lower at 
both follow-up time points for 
serotypes 6B, 18C, 19A, 19F and 
23F; IgG GMCs for serotypes 5, 
6A and 9V were statistically 
significantly lower in preterm 
infants at the 1-year follow-up 
only 
 
Kent et al. 
(2016) 49 
Open label,  
randomized, 
controlled 
multicenter 
clinical trial  
199 <35 w UK PCV13 
-group 1:  
reduced 
schedule 
(vaccine at 2 
and 4 months of 
age)  
-group 2 
accelerated 
schedule 
(vaccine at 2, 3, 
To assess the 
immunogenicity of 3 
commonly used 
PCV13 priming 
schedules in 
premature infants and 
their response to a 
12-month booster 
dose. 
-Lack of seroprotection for more 
than one-half of the PCV13 
serotypes was seen in 25%, 12%, 
and 3% of participants receiving 
the reduced, accelerated, and 
extended schedules, respectively 
(P < 0.001). 
-A reduced priming schedule of 
PCV13 resulted in higher post-
booster IgG concentrations but 
lower post-primary 
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and 4 months of 
age)  
-group 3 
extended 
schedule 
(vaccine at 2, 4, 
and 6 months of 
age)  
concentrations. 
-Later gestation was associated 
with an increase in post-primary 
vaccination IgG concentrations 
for some serotypes, while receipt 
of antenatal steroids was 
associated with decreased odds of 
seroprotection at 2 months and 
after primary immunization for 
some serotypes. 
Saroha et al. 
(2015) 42 
Prospective 
randomized 
comparative 
trial 
117 
-69 received BCG at 
birth (group 1)  
-48 received BCG at 
34 w(group 2) 
31-33 w 
  
India BCG To evaluate 
immunogenicity of 
early vs delayed BCG 
vaccination in 
moderately preterm 
(31-33 weeks) 
infants. 
-the rise of IFN-g levels measured 
6 months after BCG in 2 groups 
was comparable (p > 0.05) 
-In group 1, 39.1% infants had 
positive Mantoux reaction (5–9 
mm) 6 months after BCG whereas 
37.5% infants in group 2 had 
positive Mantoux test (p =0.473) 
-Six infants (5.12%) failed to 
develop BCG scar 
- the overall immunogenicity of 
BCG was 98.3% 
 
van den Berg 
(2015) 66 
Prospective 
randomized 
trial 
113 divided into 
2 groups: 
-1 group received 
enteral 
oligosaccharides 
mixture during days 
3–30 of life 
-1 group received 
placebo 
<32 w The 
Netherlands 
PCV 7 (4 doses 
at 2, 3, 4 and 11 
months of age) 
to investigate the 
specific antibody 
levels against the 7 
pneumococcal 
vaccine serotypes  4–
6 weeks after the 
third pneumococcal 
immunization and 4–
8 weeks after the 
booster dose 
- IgG antibody levels in preterm 
infants supplemented with 
oligosaccharides were similar to 
those of term infants at 5 months 
of age, while IgG antibody levels 
in preterm infants supplemented 
with placebo were higher for 5 of 
the 7 vaccine serotypes (serotypes 
4, 6B, 9V, 19F, 23F; P < 0.05) 
than those in term infants. 
 -At 12 months of age, there was a 
significant booster response in 
both preterm groups and the 
GMCs of pneumococcal antibody 
levels after the booster dose for all 
serotypes were not different in the 
two groups 
-preterm infants with higher 
gestational age showed higher 
pneumococcal antibody 
concentrations of certain 
serotypes at 5 and 12 months 
 
Szynczewska 
et al (2014) 
65 
Observational 
prospective 
60  
-Group I  23 born 
with birth weight 
<1000 g; 
-Group II  
37 born with birth 
weight ≥1000 g  
24-34 weeks  Polonia PCV7  
 
To assess 
concentration 
of specific 
immunoglobulin G 
against all 
seven serotypes of 
PCV7 4 weeks after 
the primary 
vaccination; prior and 
4 weeks later the 
booster dose 
administration. 
- After primary immunization, an 
increase in the average 
concentration of antibodies for all 
serotypes was observed in most 
children, with no significant 
differences between groups.  
-Serotypes 6B and 23F proved to 
be the least immunogenic 
following the primary vaccination 
-Prior to administration of the 
booster dose at age 16 months a 
significant decrease in antibody 
titer was observed in all 
children 
- The last vaccination resulted in 
another significant increase in the 
concentration of antibodies 
in both groups. 
 
Ichikawa et 
al (2013) 41 
Observational 
prospective 
Clinical trial 
161 (17 received 
early vaccination at 6 
months) 
< 34 w Japan Measles To evaluate antibody 
titers before and after 
early vaccination at 6 
months for measles  
-The antibody titers at birth was 
significantly lower in preterm 
infants born <28 weeks (P < 0.05) 
and with a weight <1000 g  (P < 
0.01).  
-At 3–6 months of age, none of 
the 108 infants tested had 
protective antibody titers.  
-Preterm infants who received 
early vaccination at 6 months kept 
antibodiy titers positive in all 
cases 1 month after vaccination.  
-Titers did not decay during the 12 
months after vaccination 
Small sample 
size 
Vermeulen et 
al. (2013) 70 
Observational 
prospective 
cohort study 
68 
-22 vaccinated with 
whole cell pertussis 
vaccine (Pw)  
-24 vaccinated with 
two components 
<31 w Belgium 3 type of 
vaccines:  
Pw,  
Pa bicomponent, 
Pa 
multicomponent  
To assess at one year 
of age the specific 
cellular 
immune responses in 
the preterm infants 
(through cytokine 
-more than half of premature 
infants vaccinated with the Pw 
vaccine or with the 2 component 
Pa vaccine developed at 3 and/or 
at 6 months of age an IFN-ɤ 
response to FHA and/or PT 
Small sample 
size 
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acellular vaccine (Pa) 
-22 vaccinated with 
three component  
Pa vaccine. 
 secretion after 
antigenic stimulation) 
- no effect of the booster dose was 
observed on the FHA or PT-
induced IFN- ɤ secretion in the 3 
groups 
- Pa vaccine induced more 
secretion of Th2 cytokines in 
response to FHA and to PT, 
compared to infants primed with a 
Pw vaccine  
Omenaca et 
al. (2012) 46 
phase IIIb, 
randomized 
double blind,  
multicenter, 
placebo-
controlled 
trial 
228 ≥ 27 and <37 w France, 
Portugal, 
Poland, 
Spain 
Rotavirus  To assess 
immunogenicity of a 
human rotavirus 
vaccine dosing IgA 
specific antibody 
concentrations 30–83 
days post-dose 2  
seroconversion rate at 30–83 days 
post dose 2 of vaccine/placebo 
was 85.7% (95% CI: 79.0– 
90.9%) in vaccine group and 
16.0% (95% CI: 8.8–25.9%) in 
the placebo group 
  
Tsuda et al. 
(2012) 47 
Observational 
prospective 
cohort 
54 <37 w Japan  Hib to evaluate vaccine 
immunogenicity in 
preterm infants by 
measuring antibody 
PRP titers as GMCs   
before and 1 month 
after the third dose 
- after three doses of vaccine, 
GMCs increased from 0.06. to 
2.89 mg/mL (P < 0.001). 
-The seroconversion rate was 
85.2% 
- the seroconversion rate after 
vaccination of infants with a 
history of antenatal exposure to 
steroids was higher than those 
without antenatal exposure (P = 
0.046). 
- the seroconversion rate of group 
vaccinated at the age of 2 months 
was close to being significantly 
worse than the group vaccinated 
at the age of >3 months (P = 
0.060) 
Small sample 
size 
 
Esposito et 
al. (2011) 48 
Prospective, 
randomized 
study 
101 -34 born <32w 
-35 born 32-36 
w 
-32 born ≥37w 
Italy Influenza 
A/H1N1 MF59-
adjuvanted 
vaccine 
 
To assess 
immunogenicity of 
influe za A/H1N1 
MF59-adjuvanted 
vaccine in preterm 
and term children 
aged 6 to 23 months 
evaluating antibody 
titers collected 
immediately before 
administration of 
dose 1, dose 2 and 4 
weeks later the dose 
2.  
-the first dose was able to 
determine seroprotection in all of 
the preterm born between 32 and 
36 weeks of gestation 
-After the administration of the 
vaccine, there was a significant 
increase in the GMCs of all the 
children (P <0.05) 
-The preterm subjects with a 
gestational age <32 weeks aged 6 
to 11 months had significantly 
lower absolute GMCs than the 
subjects in any of the other groups 
(P<0.05) 
  
Omeñaca et 
al. (2011) 54 
Prospective 
clinical trail  
286 
 
-preterm 
group I 
(between 27and 
30 w);  
-preterm group 
II 
(between 31 and 
36 w  
-term group  
 
Spain, 
Greece 
PHiD-CV  To evaluate 
immunogenicity to 
PHiD-CV at 2, 4, and 
6 months of age 
evaluating antibody 
titers like OPA o 
GMC 1 month after 
primary vaccination, 
and 1 month after 
booster vaccination. 
-at least 92.7% of 
infants in each group had antibody 
GMCs 
concentrations>0.2µg/mL and at 
least 93.2% of subjects had 
OPA titers >8 1 month after 
primary immunization. 
-preterm infants showed lower 
antibody titers for certain 
serotypes  
-at least 97.6% of subjects in each 
group developed antibody 
concentrations >0.2 µg/mL 1 
month after booster dose.  
-One month after both primary 
and booster vaccination, all 
subjects were 
seroprotected/seropositive for 
antibodies against the antigens of 
the coadministered vaccines, 
except 1 subject in preterm group 
I after primary vaccination who 
was not seroprotected 
against polio type 3. 
  
Omenaca et 
al, (2011) 53 
phase IIIb 
open, 
controlled 
multicenter 
prospective 
study  
309 -56 preterm I: 
≤31 w 
- 107 preterm II 
between 32 and 
36 w  
-150 full term 
infants 
Spain Hib-MenC-TT 
and PCV7 at 2, 
4, 6 months and 
at 16 to 18 
months of age 
to evaluate the 
immunogenicity of 
Hib-MenC-TT in 
formerly preterm 
infants measuring 
antibody specific 
titers 1 month 
postdose 3 and 1 
month after the 
booster dose. 
-the percentage of subjects with 
seroprotective anti-PRP antibody 
concentrations was ≥99% in all 
groups.  
-Booster vaccination induced 
marked increases in anti-PRP 
antibody GMCs, after a reduction 
of the percentage of subjects with 
seroprotective anti PRP before the 
booster 
-At least 99.0% and 97,3% of 
Open design  
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subjects in each age stratum had 
rSBAMenC titers ≥1:8 
postprimary vaccination and post 
booster dose respectively. 
-  At least 97.5% of infants in 
each age stratum had anti-HBs 
concentrations >10 mIU/mL at 1 
month postdose 3 
-The postdose 3 anti-HBV GMCs 
was significantly lower in the 
preterm I group than in the 
preterm II and full-term groups 
Baxter et al 
(2010) 72 
Prospective 
pragmatic 
case series 
131 <32 w UK DT-Hib-MenC-
PCV 
to show antibody 
response in premature 
infants to DT-Hib-
MenC-PCV, in a 
routine clinical 
situation  
-98.3% and 100% of premature 
infants respectively developed a 
minimum protective antibody 
response;  
-86.6% premature infants were 
protected against Men C. 
However, only 67.8% preterm 
infants achieved anti-polyribosyl 
ribitolphosphate (PRP) antibodies 
>0.15μg against Hib 
-Responses to the different 
pneumococcal serogroups ranged 
from 67.5% to 92.5%. 
- In comparison to term infants, 
preterm infants were less likely to 
achieve protective levels against 
MenC and Hib 
-Protection was inferior to 
expected based on published 
premature infant clinical trial data 
for Hib, some pneumococcal 
serotypes and Men C. 
 
Klein et al. 
(2010) 50 
Observational  
open-label 
prospective 
study 
88 
-33 ≤33 w 
-50 >37 w 
≤33-37 w USA IPV 
 
To compare the 
humoral and cellular 
immune responses of 
preterm infants to 
those of term infants 
after the primary 
series of IPV given as 
part of a combination 
vaccine 
-preterm and term infants 
developed comparable mean 
frequencies of poliovirus-specific 
memory T cell responses 
- About mononuclear cells 
(PBMCs) proliferation preterm 
infants were significantly less 
likely to have a positive 
stimulation index (SI) than term 
infants (P=0.03) 
- All infants with serum available 
for testing had a seroprotective 
antibody response to all 3 
poliovirus serotypes 
-The GMCs to poliovirus serotype 
1 was significantly lower in both 
the group of all preterm infants 
 
Moss et al. 
(2010) 
Observational 
prospective 
184 
 
-132 preterm 
infants 
-52 full term 
infants 
 
UK PCV7 
administered 
with Neisseria 
meningitidis 
group C (MCC), 
diphtheria, 
tetanus, 
pertussis, polio, 
and Hib 
vaccines 
To assess 
pneumococcal 
serotype-specific IgG 
antibody 
concentrations for all 
PCV7 4 weeks 
following the third 
immunization, and 
either at 12 months of 
age or 4 weeks after a 
booster dose of PCV7 
- only 36% term infants and 34% 
preterm infants achieved 
putatively protective levels 
against all 7 vaccine serotypes, 
- At 12 months of age, only 22% 
term infants and 11% preterm 
infants had putatively protective 
levels against all vaccine 
serotypes 
- There was a significant increase 
in GMCs for both term and 
preterm infants for all serotypes, 
including the 2 control serotypes 
from post-primary immunizations 
to post-fourth dose (P < 0.01) 
- Preterm birth adversely affected 
the GMCs to serotypes 
4, 6B, 14, 19F, and 23F (P <0.01). 
 
Omeñaca et 
al. (2010) 73 
Open label 
trial 
182 
-93 preterm infants 
-89 full term infants 
-93 preterm 
infants 
-89 full term 
infants 
Spain  DTPa, IPV, 
HBV, Hib 
To assess Hepatitis B 
response of 
premature infants 
after primary and 
booster immunisation 
with hexavalent 
vaccine 
-A total 93.4% preterm and 95.2% 
full-term infants responded to 
primary vaccination  
-Six preterm infants (6.59%) did 
not respond to primary 
immunization and failed to 
respond to the booster dose 
-No responders had a gestational 
age of at least 31 weeks and, 
except for two, were severe IUGR 
 
Faridi et al. 
(2009) 63 
Observational 
prospective 
143 
 
31-41 w India BCG To evaluate 
immunogenicity of 
-95.8% had either a reactive 
Mantoux test or positive LMIT 6 
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BCG in preterm 
infants through 
Mantoux test 
conversion at 12 
weeks and 6 months 
of age in babies 
vaccinated with BCG 
at birth  
months after BCG vaccination.  
-There were only 6 babies (4.2%) 
who did not show adequate 
responses to BCG vaccination. 
Table 4. Studies regarding vaccine immunogenicity in preterm infants [Notes: 
DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral 
polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= 
tridecavalent antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-
TT= Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille 
Calmette-Guérin vaccine; PHID-CV =PCV10-non typeable H. influenzae protein D conjugate 
vaccine; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II), MMR=measles, mumps, and 
rubella vaccine; GMCs= geometric mean concentrations; PRP= anti-polyribosylribitolphosphate; 
IPD= invasive pneumococcal disease; LMIT=leukocyte migration inhibition test]. 
 
 
 
Study 
(year) 
Design No of pts Gestational 
Age 
Location Vaccination Objectives Results Bias 
Roué et al. 
(2014) 45 
Observational 
prospective 
population-
based 
study 
201 <37 w France Rotavirus 
vaccine 
To evaluate the 
impact of the 
pentavalent rotavirus 
vaccine on the 
number of 
hospitalizations for 
rotavirus diarrhoea 
in preterm infants 
enrolled in the 
IVANHOE study. 
- After introduction 
of the vaccination program, a 2.6-
fold (95% CI, 
1.3 to 5.2) and an 11-fold (95% 
CI, 3.5 to 34.8) decrease in the 
number of hospitalizations for 
rotavirus was detected in two 
epidemic seasons in prematurely 
born infants younger than 3 years 
of age  
 
Shen et al. 
(2013) 69 
Observational 
retrospective 
683,354 (52903 
preterm infants) 
Preterm and 
full-term infants 
Canada Influenza to estimate the 
effectiveness of 
seasonal influenza 
vaccination in all 
pre- and full-term 
infants aged 6–23 
months examining 
influenza-coded 
ambulatory visits 
(physician office and 
ED visits) during 
influenza season 
periods. 
-Full vaccination was associated 
with an overall 19% reduction in 
ambulatory visits (HR = 0.81; 
95% CI, 0.68–0.97)  
-Among preterm children, full 
vaccination was associated with a 
non-significant, 28% reduction 
(HR = 0.72; 95% CI, 0.40–1.29).  
-Partial vaccination appeared 
ineffective in all groups.  
 
Rückinger 
et al (2010) 
68 
active 
prospective 
surveillance 
trial 
766,999 in 2000 
684,862 in 2007 
number of 
preterm born 
children was 
estimated based 
on the 
assumption that 
about 7% of 
children in 
Germany are 
born preterm. 
Germany PCV7 To evaluate the 
impact of PCV7 on 
IPD in preterm born 
infants comparing 
children born in 
2000 (the only birth 
cohort of 
unvaccinated 
children) with those 
born in 2007 
- A reduction in notifications of 
IPD per 100,000 from 15.0 to 8.5 
(P < 0.001) in 2007 was found. 
-A reduction in notification rate 
from 26.1 to 16.7 per 100,000 
comparing the 2000 with the 
2007 was found also in preterm 
birth cohort but it was not 
significant (P = 0.39) 
- No preterm infants with 
reported IPD had received full 
vaccination with booster dose 
according to the recommended 
scheme. In two cases a serotype 
included in PCV7 was found. 
These two cases had not received 
pneumococcal vaccination prior 
to disease onset, although they 
were at an appropriate age.  
- exact number 
of preterm born 
infants in 
Germany is 
unknown 
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 (2009) 71 
Observational 
retrospective 
nationwide 
cohort study  
 
879,424 
-preterm infants 
59,311 
-full term infants 
820,113 
≥20  Denmark Pw and Pa 
vaccine 
Effectiveness of two 
pertussis vaccines in 
preterm Danish 
children through 
evaluation of 
pertussis 
hospitalisation 
 
-For whole-cell vaccinated 
children, the difference in 
effectiveness estimated between 
preterm and full-term children 
was statistically significant (p = 
0.0134).  
-We found that preterm children 
were at 91% increased risk (95% 
CI, 21–200%) compared to full-
term children after one dose of 
whole-cell vaccine.  
 
Table 5 Studies regarding vaccine effectiveness in preterm infants. [Notes: DTaP=diphtheria, 
tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral polio vaccine; 
HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent 
antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= 
Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille 
Calmette-Guérin vaccine; PHID-CV =PCV10-non typeable H. influenzae protein D conjugate 
vaccine; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II), MMR=measles, mumps, and 
rubella vaccine; GMCs= geometric mean concentrations; PRP= anti-polyribosylribitolphosphate; 
IPD= invasive pneumococcal disease; LMIT=leukocyte migration inhibition test, IC=interval 
confidence; ED=emergency department; HR= Adjusted hazard ratios; Pw=pertussis whole vaccine; 
Pa=pertussis acellular vaccine]. 
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Figure 1  
Four-phase flow diagram of the systematic review in accordance with PRISMA guidelines[40]. 
View publication stats
